Download Your Complimentary Copy of the 2026 Agenda
The 3rd Cell & Gene Therapy Pricing & Reimbursement Summit was your unique forum to learn, network, and partner with the leaders reshaping the commercialization journey for cell and gene therapies.
Having trouble downloading the brochure? Let us know and we’ll email it to you instead.
Explore the 2026 Event Program to See What Was In Store:
Major Payer & Policy Representation
You would have heard directly from leaders at Blue Cross Blue Shield, Oklahoma Healthcare Authority, and other key stakeholders shaping coverage decisions, as they shared how evidence expectations, reimbursement pathways, and policy frameworks are evolving
Real-World Commercialization Case Studies
Attendees learned from approved companies including Autolus, Orchard Therapeutics, and Genetix Biotherapeutics as they broke down what drove uptake, what slowed access, and how they navigated real payer and provider challenges
Focused Insights on the CGT Access Model
You would have gained practical understanding of outcomes-based agreements and the Cell & Gene Therapy Access Model from the Oklahoma Healthcare Authority, including how payment structures work in practice and what this means for future pipeline assets
The Only Dedicated CGT Pricing & Reimbursement Forum
Attendees joined a focused room of biopharma, payers, policymakers, and providers at the only meeting built exclusively to address pricing, reimbursement, and access challenges for cell and gene therapies